NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
4.26
Dollar change
+0.06
Percentage change
1.43
%
Index- P/E- EPS (ttm)-4.60 Insider Own28.78% Shs Outstand0.91M Perf Week-3.18%
Market Cap3.89M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.65M Perf Month-7.39%
Enterprise Value1.94M PEG- EPS next Q- Inst Own1.61% Short Float1.85% Perf Quarter20.68%
Income-4.21M P/S- EPS this Y- Inst Trans58.28% Short Ratio0.33 Perf Half Y18.01%
Sales0.00M P/B2.08 EPS next Y- ROA-95.64% Short Interest0.01M Perf YTD30.68%
Book/sh2.05 P/C2.00 EPS next 5Y- ROE-105.70% 52W High14.80 -71.22% Perf Year-23.24%
Cash/sh2.13 P/FCF- EPS past 3/5Y33.79% 79.02% ROIC-224.24% 52W Low3.03 40.60% Perf 3Y-49.72%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility4.96% 6.76% Perf 5Y-97.43%
Dividend TTM- EV/Sales- EPS Y/Y TTM27.21% Oper. Margin- ATR (14)0.29 Perf 10Y-99.97%
Dividend Ex-Date- Quick Ratio7.73 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)44.87 Recom-
Dividend Gr. 3/5Y- - Current Ratio7.73 EPS Q/Q50.43% SMA20-5.00% Beta1.28 Target Price27.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-2.54% Rel Volume0.09 Prev Close4.20
Employees- LT Debt/Eq0.00 Earnings- SMA2004.55% Avg Volume36.99K Price4.26
IPOJan 18, 1996 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume3,158 Change1.43%
Date Action Analyst Rating Change Price Target Change
Jun-26-19Initiated Maxim Group Buy $4
Nov-10-17Downgrade ROTH Capital Buy → Neutral
Jun-27-25 04:05PM
Jun-04-25 08:50AM
Jun-03-25 08:45AM
May-14-25 06:49PM
Apr-11-25 04:15PM
06:00PM Loading…
Mar-20-25 06:00PM
Jan-03-25 04:16PM
Nov-27-24 04:05PM
Aug-19-24 04:11PM
Aug-15-24 10:53PM
May-16-24 08:54AM
Jan-25-24 04:29PM
Dec-28-23 04:15PM
Nov-14-23 07:23PM
Oct-16-23 04:37PM
07:30AM Loading…
Sep-18-23 07:30AM
Aug-28-23 12:44PM
Aug-15-23 08:46AM
Jul-27-23 07:30AM
Jan-27-23 07:00AM
Dec-15-22 07:00AM
Dec-12-22 07:49AM
Nov-17-22 05:35AM
Aug-16-22 10:53AM
Jul-11-22 08:00AM
Jul-09-22 09:07AM
Jul-05-22 08:00AM
Jun-10-22 08:00AM
Apr-25-22 01:29PM
Feb-02-22 12:27PM
08:45AM Loading…
08:45AM
Dec-21-21 08:00AM
Nov-08-21 04:15PM
Nov-05-21 04:30PM
Oct-25-21 07:15AM
Oct-12-21 08:00AM
Aug-20-21 02:52PM
Aug-04-21 09:34AM
Jun-23-21 08:00AM
Mar-31-21 04:30PM
Feb-01-21 07:30AM
Jan-15-21 09:15AM
Dec-16-20 08:00AM
Dec-01-20 04:56AM
Nov-30-20 12:50PM
Nov-16-20 08:45AM
Nov-02-20 08:00AM
Oct-30-20 08:14AM
Oct-28-20 03:00PM
08:00AM
Oct-26-20 06:30AM
Oct-15-20 08:00AM
Sep-24-20 09:00AM
Sep-18-20 04:45PM
Sep-16-20 01:05PM
Sep-15-20 08:30AM
Sep-14-20 08:30AM
Aug-26-20 05:45AM
Aug-14-20 08:45AM
Aug-10-20 04:30PM
Jul-08-20 08:00AM
Jun-24-20 08:00AM
Jun-16-20 08:00AM
Jun-01-20 05:20AM
May-15-20 08:45AM
May-11-20 04:03PM
Apr-09-20 06:15AM
Apr-02-20 09:47PM
Mar-31-20 12:43PM
Mar-30-20 04:03PM
02:30PM
Mar-26-20 08:00AM
Mar-05-20 09:00AM
Feb-18-20 08:55AM
Jan-13-20 08:00AM
Jan-07-20 09:15AM
Dec-30-19 08:00AM
Dec-17-19 10:30AM
Dec-04-19 01:22PM
Dec-03-19 09:00AM
Nov-25-19 05:15AM
Nov-14-19 04:03PM
Nov-07-19 04:30PM
Oct-22-19 08:00AM
Oct-18-19 10:23AM
Oct-16-19 09:20AM
Oct-01-19 08:00AM
Sep-18-19 08:00AM
Aug-30-19 08:01PM
Aug-23-19 11:30AM
Aug-17-19 09:59AM
Aug-16-19 07:33AM
Aug-14-19 04:03PM
07:32AM
Aug-09-19 05:00PM
Aug-07-19 09:15AM
Jul-09-19 09:00AM
Jul-03-19 10:54AM
Jun-26-19 09:10AM
Jun-04-19 07:00AM
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.